Verification experiments revealed that both ADAM17 and ATG3 were highly expressed in B-ALL patient-derived exosomes compared with those derived from healthy controls (Fig. 6A–C), which was consistent with the proteomics analysis (Supplementary Table S7). Here, ADAM17 is linked to precursor B-cell acute lymphoblastic leukemia.